Verified UK Resources for Damp, Mould & Health
For people in the UK worried about damp, mould and health
Damp and mould can worsen asthma and other respiratory conditions. For people living with aspergillosis, bronchiectasis, severe asthma or other long-term lung disease, it is reasonable to take a persistent problem seriously and ask for the underlying cause to be put right.
This guide brings together reliable UK health, housing and practical-support sources. It does not promote commercial mould testing, urine mycotoxin tests or “detox” treatments.
Health information you can trust
UKHSA and government guidance on damp and mould
The government’s consolidated guidance explains the health risks of damp and mould and the actions expected of rented-housing providers. It is the best starting point for understanding why the issue matters and why it should not simply be blamed on a tenant’s lifestyle.
UKHSA / GOV.UK: Understanding and addressing the health risks of damp and mould
NICE: indoor air quality at home
NICE guidance covers indoor air quality in homes, including damp and mould. It is helpful for understanding practical measures such as ventilation and moisture control, while recognising that tenants cannot fix structural defects or inadequate building design on their own.
NICE: Indoor air quality at home (NG149)
Asthma + Lung UK
This gives accessible advice for people with asthma and other lung conditions, including practical steps and housing-rights information for renters.
Asthma + Lung UK: Damp and mould in a rented home
Support for renters in England
Housing law differs across the UK. The following links are mainly for England; if you live in Scotland, Wales or Northern Ireland, use your local council or national housing-advice service for the equivalent rules.
Private renters
Shelter explains how to report damp and mould, what a private landlord may need to repair, and when to ask the council’s environmental-health team for help.
Shelter: Damp and mould in private rented homes
Council and housing-association tenants
Shelter provides practical guidance and letter templates for reporting damp and mould to a council or housing association.
Shelter: How to deal with damp and mould in social housing
Citizens Advice
Citizens Advice offers straightforward help on responsibility for repairs and how to take the next step when a landlord does not respond.
Citizens Advice: Damp in rented homes
Awaab’s Law: what it means for social-housing tenants in England
Awaab’s Law came into force on 27 October 2025. It introduces fixed timeframes for social landlords in England to investigate and address reported damp and mould hazards, particularly where there is a significant risk of harm.
For serious damp or mould that is not an emergency, current guidance describes a 10-working-day investigation period, followed by requirements to make a home safe and communicate the next steps. Emergency hazards must be dealt with much faster. The exact duties depend on the facts of the case, so use the current official guidance rather than relying on a general summary.
If your landlord does not act
- Keep copies of emails, letters, photographs and notes of phone calls.
- Ask your council’s environmental-health or private-rented-housing team for an inspection if the problem is serious or persistent.
- If you rent from a council or housing association, use its formal complaints process. The Housing Ombudsman explains how complaints are handled.
- Do not stop paying rent or move out without taking housing advice first; this can have serious consequences.
Practical steps at home
Small measures may reduce condensation while you wait for repairs, but they are not a substitute for a landlord fixing a leak, poor ventilation, failed heating or other building defect.
- Use fitted extractor fans where available and report them if they do not work.
- Ventilate briefly and safely when weather and security allow.
- Keep furniture slightly away from cold external walls where possible.
- Follow manufacturer safety advice for any dehumidifier or heater; never use unsafe heating methods to dry a room.
What about “toxic mould”, mycotoxins and commercial tests?
There is good evidence that damp and mouldy homes can worsen respiratory symptoms and health. That does not mean that every symptom is caused by “toxic mould”, or that expensive environmental tests, urine mycotoxin tests or detox programmes can diagnose or treat illness from a home.
The useful intervention is to identify and fix the moisture problem, remove visible mould safely where appropriate, and seek proper medical advice for symptoms. For a broader evidence review, see World Health Organization: Dampness and mould.
When to seek medical advice
Speak to your GP or usual respiratory team if damp or mould appears to be worsening asthma, cough, wheeze or breathlessness. Seek urgent help for severe breathlessness, chest pain, significant coughing of blood, blue lips or face, confusion, or rapidly worsening illness.
Last reviewed: August 2026.
🧪 Understanding Aspergillosis Blood Tests: IgE and IgG Explained
For patients in the UK and internationally
Blood tests for Aspergillus are often an important part of investigating and monitoring aspergillosis. They can be confusing because a result may be raised for several reasons, different laboratories use different methods, and no single blood test can diagnose every form of aspergillosis on its own.
This guide explains the three results people most commonly ask about: total IgE, Aspergillus-specific IgE and Aspergillus-specific IgG.
What do the different tests measure?
| Test | What it measures | How it may help |
|---|---|---|
| Total IgE | The overall level of an allergy-related antibody in the blood. | Often raised in allergic conditions, including ABPA, but also in asthma, eczema and other conditions. It is not specific to Aspergillus. |
| Aspergillus-specific IgE | Evidence that the immune system is sensitised to Aspergillus, usually A. fumigatus. | Important when investigating allergic bronchopulmonary aspergillosis (ABPA) or fungal sensitisation in asthma. |
| Aspergillus-specific IgG | A different immune response, often associated with longer-term exposure or infection. | Can support investigation of chronic pulmonary aspergillosis (CPA) and can contribute to assessment of ABPA. The laboratory method and clinical context matter greatly. |
Why the number alone is not the answer
Laboratories use different testing platforms, units and locally validated reference ranges. This means that a result cannot safely be interpreted by comparing it with a number found online or with somebody else's result. Always keep the result together with the laboratory reference range and the name of the test.
In particular, IgG results from different assays are not interchangeable. A result may be reported in mgA/L, AU/mL or another unit, with a different threshold for that assay.
How blood tests fit into ABPA assessment
ABPA is an allergic lung condition that usually occurs in people with asthma or cystic fibrosis, and sometimes in people with a compatible clinical and radiological picture. Current international guidance uses a combination of findings rather than one result.
In broad terms, clinicians look for:
- evidence of sensitisation to Aspergillus (usually a positive A. fumigatus-specific IgE);
- a total IgE of 500 IU/mL (kU/L) or above, although treatment such as oral steroids can affect the result;
- and supporting evidence, such as Aspergillus-specific IgG, a current or previous raised eosinophil count, or characteristic changes on chest imaging.
This is a diagnostic framework, not a home diagnostic test. Some people with asthma have fungal sensitisation without ABPA, and some people with suspected ABPA need repeat testing or specialist interpretation.
What about CPA?
For chronic pulmonary aspergillosis, an Aspergillus-specific IgG result can be an important clue, but it is considered alongside symptoms lasting over time, lung imaging and evidence of Aspergillus infection. A normal or only slightly raised result does not settle the question on its own, particularly if there is a strong clinical reason to investigate further.
What tests might be needed as well?
| Test or information | Why it may matter |
|---|---|
| Symptoms and medical history | Asthma control, cough, mucus, breathlessness, weight loss, previous lung disease and treatment history all change how results are understood. |
| Chest imaging | A chest X-ray or CT may show bronchiectasis, mucus plugging, cavities, nodules or other changes that help distinguish different conditions. |
| Sputum culture or PCR | May detect Aspergillus in the airways. A result still needs clinical interpretation: detecting the fungus is not always the same as proving disease. |
| Eosinophil count and lung function | Can help assess allergic airway inflammation and asthma, but can be altered by steroids and some biologic medicines. |
Can treatment affect the results?
Yes. Oral steroids can reduce some signs of allergic inflammation, including eosinophils, and biologic medicines can make eosinophil counts look lower than they were before treatment. This is one reason why your clinician may look at older blood results, repeat a test, or interpret a result differently in the light of your medicines.
For people with ABPA, total IgE is sometimes measured over time as one part of monitoring response or a possible flare. The pattern matters more than a single isolated number, and results should usually be compared using the same laboratory method where possible.
Questions you can ask at an appointment
- Which Aspergillus blood tests have I had, and what are the laboratory reference ranges?
- Does this result suggest sensitisation, infection, both, or neither?
- Do my symptoms and scan findings fit with the blood test result?
- Could my current steroid or biologic treatment affect the result?
- Would repeating the test, checking sputum, or seeking specialist advice help?
When to seek advice promptly
Seek clinical advice promptly if you have worsening breathlessness, chest pain, coughing up blood, a significant fever, rapidly worsening asthma symptoms or feel severely unwell. Blood-test results should not delay assessment of worrying symptoms.
Further reading
- Revised ISHAM guidance on diagnosing and managing ABPA
- Allergic bronchopulmonary aspergillosis (ABPA)
- Chronic pulmonary aspergillosis (CPA)
- Diagnosing Aspergillus infections in the lungs
Last reviewed: August 2026.
Weekly Aspergillosis Research Update – 24 August 2026
This week's research spans chronic obstructive pulmonary disease (COPD), fungal diagnostics, neutrophil biology and several potential antifungal strategies.
Particularly notable are a major review of the relationship between COPD and Aspergillus, a meta-analysis supporting panfungal PCR on tissue samples, and new work in Science exploring how neutrophil extracellular traps may contain inflammation during aspergillosis.
COPD and Aspergillus: an increasingly important combination
Denning DW, Bertuzzi M, Chotirmall SH, et al.
COPD and Aspergillus—a complex interaction of global health importance.
Lancet Infectious Diseases. Published 18 August 2026.
This major review brings together growing evidence that Aspergillus is an important and probably under-recognised problem in people living with COPD.
People with COPD may experience several different interactions with Aspergillus, ranging from airway colonisation and sensitisation through to chronic pulmonary aspergillosis (CPA) and invasive pulmonary aspergillosis.
The authors highlight several factors that may increase susceptibility, including damaged airways, repeated exacerbations, corticosteroid exposure, respiratory viral infections and environmental exposure to fungal spores.
The review also argues that fungal disease may sometimes be missed in patients whose deterioration is assumed to be another bacterial COPD exacerbation.
Improved investigation may therefore include fungal culture, Aspergillus PCR and, where clinically appropriate, tests such as Aspergillus IgG or antigen detection.
Why this matters: COPD is extremely common worldwide. Even if only a relatively small proportion of people with COPD develop clinically important aspergillosis, the potential number of affected patients is substantial. Better recognition could prevent repeated courses of inappropriate treatment and identify CPA or invasive disease earlier.
Panfungal PCR improves detection of invasive fungal disease in tissue
Filippidis P, El Khoury C, Cruciani M, et al.
Diagnostic performance of panfungal PCR on tissue specimens for the diagnosis of invasive fungal diseases: a systematic review and meta-analysis of the Fungal PCR Initiative (FPCRI).
Journal of Clinical Microbiology. Published 21 August 2026.
Diagnosing invasive fungal disease from tissue can be difficult. Conventional fungal culture is specific when positive but often lacks sensitivity, particularly when patients have already received antifungal treatment.
This systematic review and meta-analysis examined 28 studies evaluating panfungal PCR assays performed on tissue samples.
Panfungal PCR targets genetic sequences shared across many fungi and then identifies the fungus using sequencing. This means it can detect organisms even when clinicians did not know which fungus to look for beforehand.
The researchers found good overall diagnostic performance. Sensitivity was higher in fresh or frozen tissue than in formalin-fixed paraffin-embedded (FFPE) samples, although PCR remained useful in FFPE material.
In direct comparisons, panfungal PCR was substantially more sensitive than fungal culture.
Why this matters: Tissue biopsies are precious samples and may be difficult or risky to obtain. Adding molecular testing can increase the chance of obtaining a fungal diagnosis from tissue that would otherwise remain culture-negative.
This is particularly important for invasive aspergillosis and other invasive fungal infections where identifying the responsible organism can directly affect treatment.
How neutrophil extracellular traps may keep inflammation contained
Tsansizi LI, Guan SY, Aramburu IV, et al.
RAD51 stabilizes neutrophil extracellular traps to compartmentalize inflammation.
Science. Published 20 August 2026.
Neutrophils are among the immune system's first responders to fungal infection. One way they attack microorganisms is by releasing neutrophil extracellular traps (NETs): webs of DNA and antimicrobial proteins that can trap microbes.
This study identifies the DNA-repair protein RAD51 as an important structural component helping NETs form stable, branched networks.
In a mouse model of pulmonary aspergillosis, disrupting RAD51 reduced local containment of NET-associated inflammation. Material escaped more readily into the circulation and was associated with increased inflammatory signalling, including IL-6 and type-2 inflammatory responses.
The researchers also found associations between circulating DNA, IL-6 and eotaxin in people with aspergillosis.
Why this matters: NETs are often discussed as potentially damaging inflammatory structures. This research suggests the picture is more complicated: their architecture may also help keep inflammatory material confined to the site of infection.
Understanding how this balance works could eventually help researchers separate protective antifungal immunity from harmful inflammation.
Existing medicines repurposed to weaken fungal metabolism
Song Z, Zhao C, Wang Q, et al.
Repurposing FDA-Approved Drugs to Inhibit Fungal PPTases for Broad-Spectrum Synergy.
Advanced Science. Published 21 August 2026.
Researchers have identified fungal phosphopantetheinyl transferases (PPTases) as a potential new antifungal target.
PPTases are involved in activating enzymes needed for the production of several fungal metabolites, including molecules that contribute to virulence and fungal survival.
Rather than developing entirely new drugs from scratch, the researchers screened medicines that are already approved for other diseases and identified compounds capable of interfering with fungal PPTases.
Two drugs, tepotinib and eltrombopag, showed antifungal activity and enhanced the activity of existing antifungal treatment in experimental models. The compounds also reduced fungal burden and inflammation in a mouse model of pulmonary aspergillosis.
Why this matters: Repurposing existing medicines can sometimes accelerate drug development because much is already known about their pharmacology and safety.
However, this remains preclinical research. These medicines are not approved treatments for aspergillosis and patients should not attempt to use them for fungal disease.
Isavuconazole in aspergilloma and chronic cavitary pulmonary aspergillosis
Deviaene M, Dumoulin E, Somayaji R, et al.
Isavuconazole as an adjunctive antifungal in the multimodal management of pulmonary aspergilloma and chronic cavitary pulmonary aspergillosis: a single-centre case series.
Respiratory Medicine Case Reports. 2026;63:102486.
This single-centre case series describes the use of isavuconazole as part of the management of people with pulmonary aspergilloma and chronic cavitary pulmonary aspergillosis (CCPA).
CPA treatment often requires a combination of approaches. These may include long-term antifungal therapy, management of underlying lung disease and, in selected patients, surgery or other interventions.
Isavuconazole is one of several azole antifungals available to specialist teams and may be particularly useful in patients who cannot tolerate other azoles or where drug interactions and adverse effects make alternative treatment difficult.
Why this matters: This is only a small observational case series and cannot establish that isavuconazole is superior to other antifungals. However, it adds useful real-world evidence about its role in difficult-to-manage CPA and aspergilloma.
Our patient information page on isavuconazole has recently been updated to reflect current UK monitoring recommendations.
Read: Isavuconazole in Aspergillosis
Vanillin derivatives show experimental activity against Aspergillus fumigatus
Flores Maldonado OE, De Anda-Mora K, Jiménez-Barrientos JG, et al.
Vanillin derivatives as antifungal agents against Aspergillus fumigatus: in vitro activity, in vivo efficacy, and mechanistic insights.
Canadian Journal of Microbiology. Published 19 August 2026.
Researchers investigated vanillin and chemically related compounds for activity against Aspergillus fumigatus.
Several compounds inhibited fungal growth in laboratory experiments. The researchers also observed effects on fungal adhesion, biofilm formation and ergosterol, an important component of the fungal cell membrane.
One derivative, o-vanillin, also showed activity in an experimental model of aspergillosis.
Why this matters: New antifungal chemical structures are urgently needed as resistance to existing drugs increases.
However, these findings should not be interpreted as evidence that vanilla, vanilla extract or dietary vanillin can treat aspergillosis. The research concerns experimental antifungal compounds studied under controlled laboratory conditions.
What stands out this week?
Three themes emerge from this week's research.
- Better recognition: the COPD review reinforces how frequently fungal disease may be overlooked in patients with chronic lung disease.
- Better diagnosis: panfungal PCR is becoming an increasingly important way of identifying fungi when tissue cultures are negative.
- New treatment strategies: researchers continue to explore both new molecular targets and ways of extending the usefulness of existing antifungal drugs.
The RAD51 study also reminds us that successful treatment of aspergillosis is not only about killing the fungus. Understanding how the immune system contains infection without causing excessive inflammation remains an important part of developing better treatments.
This weekly research update summarises recently published scientific papers for general information. Laboratory and animal research is included to show where the field may be heading, but experimental findings should not be interpreted as treatments available to patients. Treatment decisions should always be discussed with an appropriate clinical team.
Isavuconazole in Aspergillosis
A balanced guide for patients and clinicians
Isavuconazole (given as the prodrug isavuconazonium sulfate) is a newer broad-spectrum triazole antifungal used in:
-
Chronic pulmonary aspergillosis (CPA)
-
Invasive aspergillosis
-
Patients who cannot tolerate other azoles
-
Selected refractory Allergic bronchopulmonary aspergillosis (ABPA) cases
It is available as oral capsules and intravenous (IV) formulation and is often chosen for its favourable tolerability profile.
1️⃣ What Isavuconazole Does
Like other azoles, isavuconazole inhibits fungal CYP51 (14-α-demethylase), blocking ergosterol synthesis and impairing fungal cell membrane formation.
It:
-
Suppresses Aspergillus growth
-
Reduces fungal burden
-
Helps stabilise lung disease
-
Provides systemic antifungal coverage
Clinical improvement is gradual over weeks.
2️⃣ How Long Is Treatment?
In CPA
-
Often 6–12 months or longer
-
May be used when other azoles cause side effects
-
Sometimes used as long-term suppressive therapy
In Invasive Aspergillosis
-
Duration depends on immune recovery and response
-
Often several months
In ABPA
-
Used selectively when other azoles are not tolerated
As with all azoles, stopping too early may lead to relapse.
3️⃣ Pharmacokinetics – Why It’s Different
Isavuconazole has more predictable pharmacokinetics than itraconazole or voriconazole.
Key features:
-
High oral bioavailability
-
Not dependent on gastric acidity
-
Food has minimal impact
-
Linear pharmacokinetics (dose–level relationship more predictable)
-
Long half-life (~100–130 hours)
Importantly:
It shortens the QT interval (unlike other azoles, which may prolong it).
This can make it preferable in patients with QT prolongation risk.
4️⃣ Do We Need Blood Level Monitoring?
Therapeutic drug monitoring (TDM) means measuring the amount of isavuconazole in the blood to help ensure that treatment is both effective and safe.
Isavuconazole has more predictable pharmacokinetics than itraconazole or voriconazole, and historically routine TDM was considered less necessary. However, experience and guidance have continued to develop.
Updated UK guidance now includes isavuconazole in recommendations for antifungal therapeutic drug monitoring. At the National Aspergillosis Centre (NAC), isavuconazole levels are monitored during treatment, particularly during long-term therapy.
Measuring levels can be particularly useful when there are concerns about:
- Treatment response or possible treatment failure
- Drug interactions
- Absorption
- Unexpected side effects
- Unusual dosing requirements
- Long-term antifungal treatment
Blood levels are interpreted alongside symptoms, response to treatment, other medicines and safety blood tests such as liver function.
Do not alter your isavuconazole dose yourself in response to a blood level or another patient's experience. Dose changes should be made by your clinical team.
5️⃣ Common Side Effects (Usually Mild)
-
Nausea
-
Vomiting
-
Diarrhoea
-
Headache
Generally fewer visual or skin-related effects compared with voriconazole.
6️⃣ Less Common but Important Effects
Liver Abnormalities
Routine liver monitoring is recommended.
Most abnormalities are mild and reversible.
Gastrointestinal Upset
Can occur early in therapy but often settles.
Infusion Reactions (IV Form)
Occasional mild reactions with IV administration.
Cardiac Effects
Unlike other azoles:
-
Isavuconazole may shorten QT interval
-
It is not associated with QT prolongation
This makes it attractive in patients with:
-
Existing QT prolongation
-
Multiple QT-prolonging drugs
However, ECG review may still be prudent in complex cardiac patients.
7️⃣ Drug Interactions
Isavuconazole:
-
Moderately inhibits CYP3A4
-
Has fewer interactions than some other azoles
Still review carefully, especially with:
-
Immunosuppressants
-
Statins
-
Certain anticoagulants
Avoid:
-
St John’s Wort
-
Strong enzyme inducers
Grapefruit has less impact than with other azoles but is generally avoided as a precaution.
8️⃣ Comparison Snapshot
| Feature | Itraconazole | Voriconazole | Posaconazole | Isavuconazole |
|---|---|---|---|---|
| Acid-dependent absorption | Yes (capsules) | No | No (tablet) | No |
| Genetic metabolism impact | Low | High (CYP2C19) | Low | Low |
| QT prolongation | Minimal | Possible | Possible | No (shortens QT) |
| Visual side effects | Rare | Common | Rare | Rare |
| TDM required | Yes | Essential | Recommended | Recommended in UK guidance |
| Long-term tolerability | Moderate | Sometimes limited | Often good | Often very good |
Balanced Summary for Patients
Isavuconazole is a newer antifungal that is often easier to tolerate and has more predictable levels in the body. Blood tests and monitoring help ensure treatment remains safe and effective.
Clinician Checklist
-
Confirm indication and prior azole exposure
-
Baseline liver function tests
-
Review interacting medications
-
Consider ECG if complex cardiac history
-
Arrange TDM according to current guidance and local protocol
Updated August 2026: The section on therapeutic drug monitoring (TDM) has been revised to reflect updated UK guidance and current practice for monitoring isavuconazole treatment.
“It Worked for Me”: How to Use Health Advice from Patient Support Groups
Patient support groups can be an extraordinary source of information.
Someone who has lived with aspergillosis for ten years may be able to tell you things about fatigue, coughing, medication, appointments and everyday life that you will never find in a medicine information leaflet.
That lived experience is valuable.
But there is an important difference between someone telling you what happened to them and telling you what you should do.
Learning to recognise that difference can help you get the enormous benefits of patient communities without being misled by well-intentioned advice.
Why patient experience matters
Medical information usually tells us what happens to groups of people. Patient communities tell us what illness and treatment can actually feel like to an individual.
Someone might explain how they organise their medicines, cope with fatigue, manage nebulisers when travelling, deal with changes in taste or find the confidence to ask their consultant about a troublesome side effect.
They can also provide something equally important: reassurance that somebody else understands.
Research into online patient communities confirms that useful information and support are exchanged in these groups. However, research also finds inaccurate and misleading medical information, particularly in discussions about long-term and serious conditions.
A 2025 scoping review of health information in online peer-support groups found evidence of both good-quality information and misinformation. Importantly, the researchers also found that other patients frequently played an active role in correcting inaccurate claims.
The challenge isn't to stop listening to other patients. It is to recognise what kind of information they are giving you.
Experience, interpretation and advice are different things
Consider three statements:
1. Experience
“I started itraconazole and felt nauseous.”
That is someone's personal experience. There is no reason to dispute it.
2. Interpretation
“Itraconazole caused my nausea.”
That may well be correct, but now an interpretation has been added. Nausea has many possible causes and sometimes establishing whether a medicine is responsible requires clinical assessment.
3. Advice
“Itraconazole made me ill, so you shouldn't take it.”
Now the statement has changed completely. One person's experience has become medical advice for another person.
That is where caution is needed.
The most useful question you can ask
When you read health information in a patient group, ask yourself:
“Is this person telling me what happened to them, or telling me what I should do?”
Personal experience can be extremely useful.
Instructions about changing your treatment require a much higher level of evidence.
Why completely honest patients can give conflicting advice
One person may say an antifungal transformed their life. Another may say the same medicine did nothing. A third may have experienced significant side effects.
All three can be telling the truth.
People differ in their diagnosis, severity of disease, other medical conditions, other medicines, drug absorption, genetics and many other factors.
Even two people who both say they have “aspergillosis” may have very different diseases.
Allergic bronchopulmonary aspergillosis (ABPA), chronic pulmonary aspergillosis (CPA), an aspergilloma and invasive aspergillosis are not interchangeable diagnoses. A treatment that is essential for one person may be unnecessary or inappropriate for another.
Before comparing your treatment with somebody else's, therefore, one of the first questions should be:
“Do we actually have the same condition?”
Why frightening stories can seem more common than they really are
Imagine 100 people start a medicine.
Most take it without anything particularly interesting happening. A few experience dramatic side effects.
Who is most likely to write a long social media post about it?
Probably someone in the second group.
This doesn't make their experience untrue or unimportant. But reading patient discussions cannot tell you how frequently something happens.
People experiencing problems often have a particularly strong reason to seek help and post about them. People whose treatment is working uneventfully may have much less reason to say anything.
This is one reason online discussions can unintentionally make rare or unusual experiences appear commonplace.
“It worked for me” doesn't prove that a treatment works
The opposite problem occurs when somebody improves after trying a treatment, supplement, diet or other intervention.
If somebody says:
“I tried this and felt much better.”
their improvement may be completely genuine.
But that alone cannot establish why they improved.
The underlying illness may have changed, another treatment may have started working, symptoms may naturally have fluctuated, or several things may have changed simultaneously.
This is one reason clinical trials compare groups of patients rather than simply collecting success stories.
A testimonial can tell you that someone improved. It cannot by itself prove that the treatment caused the improvement.
Be particularly cautious when someone tells you to stop treatment
Statements such as these deserve particular caution:
“Stop taking it.”
“Reduce the dose yourself.”
“You don't need that medicine.”
“Replace it with this supplement instead.”
There may be circumstances in which a medicine genuinely does need to be stopped or changed, particularly if serious side effects occur.
But another patient usually cannot know enough about your medical circumstances to make that decision for you.
If a patient describes a side effect that sounds similar to something you are experiencing, their experience may provide an extremely useful prompt to contact your doctor, pharmacist or specialist team.
That is very different from using their experience to change your own prescription.
Watch out for absolute statements
Medical misinformation often sounds unusually certain.
Be cautious about statements containing words such as:
- always
- never
- everyone
- no one
- guaranteed
- cure
For example:
“Everyone with aspergillosis needs antifungals.”
That isn't correct. Different forms and clinical states of aspergillosis require different approaches.
Equally:
“Antifungals are toxic and should be avoided.”
is an unjustified generalisation from the fact that antifungals can cause important side effects in some people.
Good medical information often contains apparently less exciting words such as may, can, usually, in some patients and depending on the circumstances.
That isn't uncertainty caused by ignorance. It often reflects the reality that medicine is complicated.
Popularity isn't the same as evidence
A comment with dozens of likes can still be wrong.
Repeated claims can also start to feel more trustworthy simply because we have encountered them several times.
Patient communities can unintentionally amplify particular beliefs as people repeat information they originally heard from somebody else.
Before accepting an important medical claim, try to find out where it originated.
Was it:
- a patient's personal experience?
- something their doctor apparently told them?
- a newspaper story?
- a research paper?
- a clinical guideline?
- an NHS or specialist medical information source?
These aren't equivalent forms of evidence.
“My doctor said...” can still be difficult to interpret
People frequently share advice given by their own doctors, and this can be very useful.
But there is another important qualification.
The doctor was advising that particular patient.
There may have been scan findings, blood results, previous treatments, other illnesses or medications influencing that advice which aren't mentioned in the social media post.
Even accurately remembered medical advice can therefore become misleading when removed from the circumstances in which it was given.
Check extraordinary claims
If you encounter something surprising – particularly a claim that contradicts what your medical team has told you – don't assume either source must automatically be wrong.
Check it.
Reliable places to look include NHS information, recognised professional organisations, published clinical guidelines and specialist centres with expertise in the condition.
You can also take the question back to your clinical team:
“I've read this in a patient group. Does it apply to me?”
That is a perfectly reasonable question.
What should moderators do about incorrect information?
Good patient communities do not need to remove every incorrect statement.
People should normally be able to describe their own experiences – including difficult, unusual or negative experiences.
But there is an important distinction between:
“This happened to me.”
and:
“Everyone should do this.”
When a claim could cause somebody to stop necessary treatment, take an inappropriate treatment or misunderstand the seriousness of their condition, it is reasonable for moderators or knowledgeable members to add accurate information.
Research suggests that this kind of correction already happens naturally in patient communities. A 2025 scoping review of online peer-support groups found that fellow members often responded to false claims or subsequently provided correct information.
The researchers also suggested that clinical and academic experts could have a valuable role in helping to improve the quality of health information shared in these communities.
The objective isn't to win an argument. It is to make sure that somebody reading the discussion six months later sees reliable information alongside the original claim.
A simple five-question check
Before acting on health advice from Facebook, Telegram or another patient community, ask:
- Is this personal experience or medical advice?
- Does this person actually have the same condition as me?
- Are they telling me to start, stop or change a treatment?
- Can I confirm the claim using a reliable medical source?
- Should I ask my clinical team whether this applies to me?
If the proposed action could significantly affect your health, questions four and five become particularly important.
Another useful way to check health information
NHS England has developed a free resource called Misinformation UnMASKED to help people decide whether health information they encounter online can be trusted.
It includes practical guidance for checking online health information and is designed for patients, families and carers as well as health and care staff.
Visit NHS Misinformation UnMASKED – checking online health information.
Patient groups and medical professionals provide different things
This doesn't mean doctors are always right and patients are always wrong.
That would miss much of the value of patient communities.
A clinician may know far more about the evidence supporting a treatment. Someone who has taken that treatment for five years may know far more about what taking it every morning actually feels like.
Those are different kinds of knowledge.
The best patient communities bring them together.
Keep sharing your experiences
None of this should discourage people from talking openly about treatment.
If a medicine helped you, tell people.
If you experienced a side effect, tell people.
If you found a useful way of managing fatigue, mucus clearance, appointments or everyday life, other patients may benefit enormously from hearing about it.
Just remember the small distinction that makes patient communities safer:
Share what happened to you. Be much more cautious about telling somebody else what should happen to them.
That allows patient experience to remain one of the greatest strengths of a support community without accidentally turning experience into a prescription.
Online patient communities can provide valuable peer support and lived experience, but they cannot replace individual medical advice. If you are considering changing prescribed treatment, discuss it with your doctor, pharmacist or specialist team.
I've Been Diagnosed with ABPA – Do I Really Need Steroids and Antifungals?
Being diagnosed with allergic bronchopulmonary aspergillosis (ABPA) can be frightening. Then you read about the medicines used to treat it – corticosteroids such as prednisolone and antifungal medicines such as itraconazole – and their lists of possible side effects can be frightening too.
It is quite reasonable to wonder: would I be better off taking nothing?
The answer isn't simply “take every medicine you are offered”. ABPA varies considerably between people, and modern treatment is increasingly individualised. The aim is to control the disease while exposing you to as little treatment – and as few side effects – as reasonably possible.
Why is ABPA treated?
ABPA is not the same as an invasive fungal infection. In ABPA, Aspergillus growing in the airways triggers an excessive immune and inflammatory response.
This can cause worsening asthma, coughing, wheezing, mucus plugging and exacerbations. Repeated or poorly controlled inflammation can also contribute to permanent changes in the lungs, including bronchiectasis.
Treatment therefore has two main approaches:
- Corticosteroids reduce the damaging allergic inflammation.
- Antifungal medicines reduce the amount of Aspergillus in the airways and therefore reduce one of the triggers for that inflammation.
But that does not mean everyone with ABPA automatically needs both.
Do I have to take prednisolone?
Not necessarily.
Oral corticosteroids such as prednisolone are very effective at suppressing the inflammation caused by active ABPA and have therefore been a mainstay of treatment for many years.
However, systemic steroids can cause significant side effects, particularly when used repeatedly or for prolonged periods. These can include changes in mood and sleep, increased appetite and weight gain, raised blood glucose, thinning of the bones and skin, increased susceptibility to infection and suppression of the body's own production of cortisol.
Doctors therefore try to balance the benefits against these risks.
The 2024 international ISHAM guidelines recommend a low-to-moderate dose course of oral prednisolone, tapered and completed over several months, as one first-line option for acute ABPA.
But it is not the only first-line option.
Do I have to take an antifungal?
Again, not necessarily.
Itraconazole is another recommended first-line treatment for acute ABPA and may be particularly useful when systemic corticosteroids are contraindicated or undesirable.
Antifungals can cause side effects and interact with other medicines. Azoles such as itraconazole are processed by the liver and can occasionally cause liver problems.
That doesn't mean that taking an azole will damage your liver.
Doctors can use blood tests to monitor liver function and, in some circumstances, measure the amount of antifungal medicine in the blood. Medication interactions also need to be checked carefully.
If one antifungal cannot be tolerated, that does not necessarily mean every antifungal will cause the same problem. Other treatment options may sometimes be considered by the specialist team.
Do I need steroids and an antifungal?
This is an important area where treatment thinking has changed.
For newly diagnosed acute ABPA, the 2024 ISHAM international guidelines recommend either:
- oral prednisolone, or
- oral itraconazole
as initial treatment.
They do not recommend routinely giving prednisolone and itraconazole together as first-line treatment for acute ABPA. Combination treatment has a more important role in people experiencing recurrent ABPA exacerbations.
There are exceptions, and your specialist may have good reasons for recommending a particular regimen based on your previous treatment, lung disease, scans, blood results, other illnesses and medications.
If you are concerned about being prescribed both medicines, it is reasonable to ask your specialist:
“Why have you recommended both treatments in my particular case?”
Does everyone diagnosed with ABPA need treatment?
No.
The 2024 international guidelines do not recommend routine systemic treatment for people with asymptomatic ABPA.
People with serological ABPA (ABPA-S), where there is no ABPA-associated bronchiectasis on CT, may also not require systemic treatment if their asthma is well controlled and they are not experiencing recurrent exacerbations.
This is another reason why somebody else's experience of ABPA may not apply to you.
What happens if I don't treat it?
This depends on your individual disease.
It is wrong to say that everybody with untreated aspergillosis will die. “Aspergillosis” describes several very different diseases.
However, active ABPA should not simply be ignored. Repeated inflammation and mucus plugging can damage the airways and contribute to bronchiectasis. Early identification and appropriate treatment are intended to control the disease and reduce that risk.
If fear of medication is making you consider refusing treatment, tell your doctor. There may be more than one reasonable treatment strategy to discuss.
What does “Stage 4 ABPA” mean?
You may encounter numbered ABPA stages on older websites, patient forums and medical papers.
These numbers can be misleading because they were not like cancer stages, where a higher number necessarily means more advanced disease.
In the previous ISHAM classification, for example, Stage 4 meant remission.
The 2024 international guidelines have moved away from numbered stages and instead describe five clinical states:
- acute ABPA
- response
- remission
- treatment-dependent ABPA
- advanced ABPA
So statements such as “Stage 4 aspergillosis is terminal” are incorrect.
It is also important to distinguish ABPA from chronic pulmonary aspergillosis (CPA), aspergilloma and invasive aspergillosis. They are different diseases with different treatments and outlooks.
What if the first treatment causes side effects?
Contact your clinical team.
Don't assume that experiencing a side effect means you have only two choices: endure it or abandon treatment altogether.
Depending on the circumstances, clinicians may be able to alter the treatment, investigate whether the symptom really is caused by the medicine, or consider another approach.
For people with recurrent or treatment-dependent ABPA, specialist treatment options can also include longer-term azole therapy, nebulised amphotericin B and, in selected patients, biological medicines.
ABPA treatment is no longer simply a choice between “steroids or nothing”.
What about biological treatments for ABPA?
Biological medicines – often called biologics – are becoming increasingly important in the treatment of difficult-to-control asthma and ABPA.
These medicines target specific parts of the immune response involved in allergic and eosinophilic inflammation. They include omalizumab, mepolizumab, benralizumab, dupilumab and tezepelumab.
Biologics are not currently recommended as routine first-line treatment for a new episode of acute ABPA. Steroids and/or antifungal treatment remain the usual initial approaches.
However, biologics may be considered in some people with treatment-dependent or recurrent ABPA, particularly when severe asthma is also present or repeated courses of oral corticosteroids are causing problems.
One important potential advantage is their steroid-sparing effect: controlling the underlying allergic inflammation may allow some patients to reduce their exposure to systemic corticosteroids.
Omalizumab has the longest history of use in ABPA, but there is increasing experience with other biologics targeting different parts of the inflammatory pathway. Which, if any, is appropriate depends on the individual's asthma, ABPA, blood results, previous treatments and other clinical factors.
Research in this area is developing rapidly, so the role of biologics in ABPA treatment is likely to continue evolving.
A particular warning about antifungals and sunlight
You may occasionally see claims that sitting in the sun or “heliotherapy” can help the inflammation associated with aspergillosis.
Sunlight is not a recognised treatment for ABPA.
There is an additional reason to be cautious if you take certain antifungals.
Voriconazole can cause significant photosensitivity. People taking it are advised to protect themselves from sunlight because prolonged treatment is also associated with an increased risk of phototoxic skin damage and squamous cell carcinoma.
Always check the advice for the particular medicine you have been prescribed.
Patient experiences are valuable – but they aren't prescriptions
Patient support groups can be enormously helpful.
One person may tell you that itraconazole transformed their symptoms. Another may have stopped it because of side effects. Someone else may have taken corticosteroids for years, while another person has hardly needed them.
All of those experiences can be genuine.
But none tells you what will happen to you.
When reading patient discussions, it can help to separate:
“This is what happened to me.”
from:
“This is what you should do.”
The first can be extremely valuable. The second needs much more caution.
Questions to ask your doctor
If you have recently been diagnosed with ABPA and are worried about treatment, consider asking:
- How active or severe is my ABPA at the moment?
- What are we trying to achieve with this treatment?
- Why have you chosen this particular medicine for me?
- Do I need a steroid, an antifungal, or both?
- How long do you expect me to take it?
- What side effects should I report?
- What blood tests or other monitoring will I need?
- What happens if I cannot tolerate this treatment?
- How will we know whether it is working?
Understanding the purpose of treatment often makes the decision much less frightening.
The important message
A new diagnosis of ABPA does not mean that you are inevitably going to become seriously ill, nor does it mean that you must simply accept whatever side effects treatment causes.
ABPA is treatable, and there are now several approaches to managing it.
The aim is to find the treatment that controls the disease effectively while minimising its impact on the rest of your health.
If you are worried enough about a prescribed treatment that you are considering not starting it or stopping it, talk to your clinical team before making the change. There may be alternatives or adjustments that you have not yet discussed.
This information is intended to help people understand ABPA and its treatment. It does not replace individual advice from your doctor or specialist aspergillosis team.
The Thursday Sessions: Living with Aspergillosis Day to Day
Every Thursday at 10 am UK time, people affected by aspergillosis, relatives and carers meet online for a friendly, guided discussion. You can join in, ask a question, share an experience or simply listen. There is no need to book.
See the next Thursday meeting and join here. Please use this page for the current joining link and final details.
Our recent topic was: what parts of everyday life have changed most since aspergillosis became part of it?
The answers were varied, because everyone’s health, treatment and triggers are different. But several shared themes emerged: learning what affects you, protecting your limited energy, finding ways to remain connected, and building confidence to speak up for what you need.
Finding people who understand
For many people, receiving a diagnosis can be a relief but also the start of a steep learning curve. Aspergillosis is unfamiliar to many friends, relatives and even some healthcare professionals. That can leave people feeling they have to explain the condition repeatedly—or that others cannot see how unwell they are because they do not “look ill”.
Talking with others who have similar experiences can make a real difference. It creates space for practical tips, but also for the simple recognition that breathlessness, fatigue, medication effects and uncertainty are real. Sometimes it is enough not to have to explain everything from the beginning.
Learning your own patterns and triggers
People described gradually noticing that some places or situations can make symptoms worse for them. Examples included damp or musty environments, piles of decaying leaves, strong fragrances and aerosol sprays, busy indoor spaces, and situations where the risk of respiratory infection feels higher.
These experiences are personal, not a list of rules. What bothers one person may not affect another. The useful approach is to notice patterns, discuss important concerns with your clinical team, and make sensible adjustments where you can.
Plan ahead—but leave room to change your mind
A recurring challenge was the unpredictability of symptoms. Plans may have to change because of fatigue, breathlessness, infection risk or a difficult treatment day. Some people find it helps to choose flexible arrangements: meet at a quieter time, choose a familiar venue, arrive early, sit near an exit, or avoid buying non-refundable tickets far in advance.
Planning can also make social life more possible. One person described going out with family while choosing not to eat, so they could still enjoy the company without worrying about food-related symptoms. Others found low-pressure ways to see people, such as a quiet coffee, an exercise session at their own pace, or inviting a friend to their home.
Protect your energy
Living with a long-term lung condition often means making choices about where to spend your energy. This may include pacing activities, saying no without guilt, and recognising when a conversation, errand or social commitment is simply too demanding on that day.
Protecting energy is not giving up. It is an active way of making room for the things that matter most. Several people spoke about the value of accepting help, using a temporary solution when a problem cannot be solved immediately, and returning attention to what is manageable today.
Be informed and keep useful records
Participants felt that understanding their own condition helped them feel more in control, especially when they met professionals who had limited experience of aspergillosis. Reliable information can help you prepare for appointments and ask clearer questions.
A simple symptom diary or personal health file can be useful. You might record changes in symptoms, medicines and side effects, test results, questions for clinic, and the contacts who know your care. This is particularly helpful when different services use incomplete or outdated information.
Always take medicines as prescribed, and if you have a possible side effect or another concern, seek advice from your treating team rather than stopping a medicine on your own.
Acceptance, hope and boundaries
Acceptance came up repeatedly—not as liking the restrictions that illness can bring, but as recognising the reality of the condition and then finding a way forward. For some, that means focusing on useful information; for others, it means stepping back from negativity, choosing supportive people, or allowing a difficult day to be just that.
There is no single right way to live with aspergillosis. Small adaptations can add up: learning what helps, keeping your support network close, and being kind to yourself when plans need to change.
Join the conversation
Thursday meetings begin with a suggested everyday topic, then open into a relaxed group conversation. They are a chance to hear how others approach the same challenges, pick up practical ideas and feel less alone. You do not have to speak or turn your camera on.
Weekly peer-support discussions are not recorded, so people can speak freely. Join us next Thursday at 10 am UK time: see the meeting details and current joining link.
This article summarises themes from a patient discussion. It is not individual medical advice. Please discuss your own symptoms, medicines and risk factors with your clinical team.
More Thursday Sessions: explore discussion summaries and find out how to join.
Join our online aspergillosis meetings
Our online meetings offer information, shared experience and friendly peer support for people affected by aspergillosis, along with relatives and carers. You are welcome whether you are newly diagnosed, have been living with aspergillosis for many years, or simply want to understand more.
There are two easy ways to keep up to date: our website has the full, current meeting details and joining links; our Facebook group helps you discover upcoming meetings and receive reminders.
Need to join a meeting?
Go straight to our Online meetings page. It is the one page to bookmark. There you can quickly:
- see the next meeting and its UK start time;
- read the topic and any joining information; and
- open the current joining link when it is time to attend.
If you use Facebook, look in the group’s Events section as well and click Interested or Going to receive a reminder. The Event will always send you back to the website for the joining link.
1. Start with the Online meetings page
The Online meetings page is the best place to check what is happening and to join. It contains the current date, time, topic and joining link for each meeting.
We may occasionally need to change a speaker, topic or link. For this reason, please return to the website shortly before the meeting rather than relying on an old link in a social-media post or email.
You do not normally need to book a place in advance. Simply open the joining link a few minutes before the meeting starts.
2. Use Facebook Events for reminders
If you use Facebook, join our Facebook group and look for Events in the menu below the group cover image. On a phone, tap More if you cannot see Events straight away. This shows meetings that are coming up.
Open the Event and click Interested if you hope to attend, or Going if you expect to be there. Facebook can then send you its usual reminders, depending on your own notification settings.
The Facebook Event will direct you back to the Online meetings page for the definitive information and joining link. Please check the Event as well as the website near the time of the meeting, as we may post a practical update there.
3. Choose the meeting that suits you
- Tuesday social meeting, 2 pm UK time: an informal opportunity to say hello and talk with other people.
- Thursday discussion, 10 am UK time: a friendly group discussion, sometimes with a suggested topic to get the conversation started.
- First Friday monthly meeting, 1 pm UK time: a longer session with talks, discussion and practical information, usually held on Microsoft Teams.
If you live outside the UK, please check the time difference where you are. The current meeting page will always show the UK time.
4. Join the meeting
- Open the joining link from the Online meetings page a few minutes early.
- Enter the name you would like others to see. A first name, initials or a nickname are all fine.
- Allow microphone access if you would like to speak.
- Choose whether to turn on your camera. It is completely fine to join with it off.
- Wait for the host to let you in, if the meeting uses a waiting room.
Most meetings can be joined using a browser on a computer, tablet or phone. You do not usually need to create an account. Microsoft Teams may offer its app, but you can normally choose to join in your browser instead.
Want to see what Thursday Sessions are like? Explore previous discussion summaries.
Come in as you are
You can join late, leave early, listen quietly, use the chat, or speak when you feel ready. There is no pressure to share personal information. If it is your first meeting, joining a few minutes early can make the technology feel less rushed.
Our meetings are for information and support, not individual medical advice. Please continue to discuss symptoms, treatment decisions and urgent health concerns with your own clinical team.
Privacy and recordings
Weekly peer-support discussions are not recorded, so people can speak more freely. Some planned monthly presentations may be recorded; if so, we will say so clearly at the start. Please respect everyone’s privacy and avoid posting personal medical information in Facebook Event discussions.
If you cannot join
First, check the Online meetings page for the most up-to-date link. You can also try opening it in another browser such as Chrome, Edge or Safari. If you miss a recorded monthly presentation, useful recordings and resources may be available on our Recorded patient meetings page.
We hope to see you at a meeting soon.
Cleaner air is lung care: why the ULEZ study matters for asthma, bronchiectasis and aspergillosis
A major new UK study has found that children living in central London experienced faster lung-function growth after traffic-related air pollution fell following the introduction of the Ultra Low Emission Zone (ULEZ).
This does not mean that ULEZ treats aspergillosis, asthma or bronchiectasis. But it is an important reminder that the air around us is part of lung health. For people already living with a respiratory condition, cleaner air can mean one less pressure on lungs that may already be inflamed, damaged or working hard.
What did the study find?
The Children’s Health in London and Luton (CHILL) study followed 3,414 children aged 6–9 years in central London and Luton. The researchers measured lung function each year and estimated exposure to nitrogen dioxide (NO2), a pollutant strongly linked to traffic exhaust.
Before ULEZ was introduced, children in London had greater traffic-pollution exposure and poorer measured lung function than the comparison group in Luton. Over the following years, NO2 exposure fell faster in London and the children’s lung function grew faster too. A key measure, FEV1 (the amount of air someone can blow out in one second), caught up with the Luton group.
This was not a simple before-and-after comparison. Luton was included to help account for wider changes that affected both places, such as the COVID-19 pandemic and general changes in traffic. The study cannot prove that ULEZ alone caused every improvement, but it provides strong evidence that reducing traffic pollution can benefit children’s lung development.
Why does this matter if you already have a lung condition?
Air pollution does not cause every respiratory illness, and it does not cause aspergillosis directly. Aspergillosis is caused by infection or an allergic response to Aspergillus fungi. However, polluted air can irritate and inflame the airways, increase cough and breathlessness, and trigger worsening symptoms in people with asthma, COPD and other lung conditions.
Many people with aspergillosis also have asthma, bronchiectasis, COPD or previous lung damage. For them, a pollution episode may be another trigger alongside infection, allergens, cold air, smoke or exertion. Reducing pollution cannot replace treatment, airway-clearance techniques, inhalers, antifungal medicines or clinical care. It can reduce one avoidable stress on the lungs.
Cleaner air is about the future as well as today
The most striking lesson from this study is that lungs are not entirely fixed in childhood. When traffic pollution fell, the children’s lung-function growth accelerated. This suggests that reducing exposure while lungs are still developing can allow important catch-up.
That matters for every generation. Children who grow up with healthier lungs may enter adult life with more respiratory reserve. In later life, that could mean greater resilience when faced with asthma, infections, smoking, occupational exposures or other lung disease.
For adults with established lung disease, cleaner air is less likely to reverse structural damage. But it can still matter greatly: fewer bad-air days may mean fewer symptom flare-ups, more confidence to be active and less pressure on already vulnerable lungs.
What can individuals do?
Air pollution is a public-health issue, so the main solutions must be collective: cleaner vehicles, cleaner public transport, safer walking and cycling routes, well-insulated homes with clean heating, and action on sources such as traffic and wood burning.
There are also small practical steps that may help on days when air quality is poor:
- Check the local air-quality forecast before planning outdoor activity.
- Where possible, choose quieter routes away from heavy traffic rather than stopping activity altogether.
- Avoid adding to indoor air pollution: do not smoke indoors, and take care with wood or coal burning.
- Continue your prescribed medicines and airway-clearance routine.
- Follow your usual action plan and seek clinical advice if worsening breathlessness, wheeze or chest symptoms are not settling.
For most people, the benefits of staying active remain important. The aim is not to make people fearful of going outside, but to make it easier for everyone to breathe cleaner air while doing so.
A public-health benefit we can now see
Measures such as clean-air zones can be controversial, particularly when the cost of replacing an older vehicle falls on individuals or small businesses. That makes fair transition support essential.
But this study gives the public-health benefit a much clearer human meaning. Cleaner air was associated not only with a lower number on a pollution monitor, but with children’s lungs growing better. For people living with aspergillosis, asthma and bronchiectasis, that is a reminder that clean air is not a luxury or simply an environmental aspiration. It is part of prevention, part of respiratory care, and part of giving future generations a healthier start.
Further information
- Read the CHILL study in The Lancet Public Health
- Plain-language summary from the CHILL research team
- Check the UK air-quality forecast
This article is for general information and is not a substitute for personal medical advice. Contact your clinical team if worsening respiratory symptoms are not responding to your usual management plan.
Nebulised saline: what do 0.9%, 3%, 6% and 7% actually mean?
People with bronchiectasis and other long-term lung conditions are sometimes advised to inhale saline through a nebuliser to help with airway clearance. If you have been prescribed it, you may have noticed that saline comes in different strengths — commonly 0.9%, 3%, 6% or 7%.
So what do those numbers mean? Is stronger saline better? And why can one person comfortably use 7% saline while another finds even 3% makes them cough or wheeze?
The answer is that nebulised saline is not simply “salt water”. Its concentration changes how it interacts with the surface of the airways and with mucus.
Why use nebulised saline?
Healthy airways are lined by a thin layer of fluid. Tiny hair-like structures called cilia beat through this fluid, helping move mucus and trapped particles towards the throat, where they can be coughed up or swallowed.
In bronchiectasis, mucus can become unusually thick and difficult to clear. Damaged and widened airways can also allow mucus to accumulate, creating an environment in which bacteria and other microorganisms can persist.
Nebulised saline can help by adding water to the airway surface and making secretions easier to move and cough up. It is generally used alongside an airway-clearance technique rather than instead of one.
Current European bronchiectasis guidance suggests considering mucoactive treatments when airway-clearance techniques alone have not adequately controlled symptoms. Treatment should be individualised, taking account of tolerability and treatment burden.
What does the percentage mean?
The percentage tells you how much sodium chloride — ordinary salt — is dissolved in the sterile solution.
0.9% saline — isotonic or “normal” saline
A 0.9% sodium chloride solution has approximately the same salt concentration as body fluids, which is why it is described as isotonic.
When nebulised, it moistens the airways and can help loosen secretions. British Thoracic Society guidance suggests considering humidification with sterile water or normal saline to facilitate airway clearance.
Because it is relatively gentle on the airways, 0.9% saline may be useful for people who cannot tolerate stronger solutions.
3% saline — mildly hypertonic
Anything above 0.9% is described as hypertonic saline.
The higher salt concentration creates an osmotic effect that helps draw water towards the airway surface. This can increase the hydration of mucus and make it easier to move.
Three per cent saline therefore provides a stronger effect than normal saline while potentially being easier to tolerate than 6% or 7%.
It can be a useful compromise for someone who benefits from hypertonic saline but develops excessive coughing, chest tightness or wheezing with a higher concentration.
6% and 7% saline — hypertonic saline
Six and seven per cent saline have been studied as airway-clearance treatments in bronchiectasis and are commonly encountered in respiratory practice.
The principle is the same: the concentrated salt solution draws water towards the airway surface, helping hydrate thick secretions so that airway-clearance techniques and coughing can remove them more effectively.
British Thoracic Society guidance describes hypertonic saline as saline at 3% or above and suggests evaluating isotonic or hypertonic saline when airway clearance is inadequate, particularly where secretions are viscous or there is sputum plugging.
Does stronger mean better?
Not necessarily.
It is tempting to think:
0.9% → 3% → 6% → 7% = increasingly effective treatment.
Biologically, increasing the concentration can produce a greater osmotic effect. But what matters clinically is whether that translates into a useful improvement for the individual person.
The evidence is less clear-cut than might be expected.
Some relatively small studies have found improvements in sputum clearance, ease of expectoration, lung function or quality of life with hypertonic saline. However, other studies have found that normal saline also produces worthwhile benefits.
The British Thoracic Society concluded that hypertonic saline may improve sputum clearance and quality of life, but that it was uncertain how much additional benefit it provided over isotonic saline.
More recently, a systematic review and meta-analysis found that, overall, hypertonic saline produced results comparable with control treatment — which included isotonic saline in some studies — for outcomes including lung function and pulmonary exacerbations. The available evidence remains limited and further trials are needed.
So 7% is not automatically “better treatment” than 3%, and 3% is not automatically better than 0.9%.
The best concentration is the one that provides useful mucus clearance while remaining tolerable enough to use regularly.
Why does hypertonic saline make me cough?
Coughing is partly the point: mobilising mucus and making it easier to cough up is one reason saline is used.
But hypertonic saline can also irritate sensitive airways.
Some people experience:
- increased coughing
- wheezing
- chest tightness
- breathlessness
- throat irritation or an unpleasant salty taste.
This is particularly important for people who also have asthma or bronchial hyper-responsiveness.
For this reason, British Thoracic Society guidance recommends an airway-reactivity challenge when inhaled mucoactive treatment is first given. It also advises considering treatment with a bronchodilator beforehand in people at greater risk of bronchoconstriction, including those with asthma or very severe airflow obstruction.
This is one reason people should not simply decide for themselves to move from 3% to 7% saline because the higher number sounds more effective.
What if I cannot tolerate 7% saline?
This is an important point.
Being unable to tolerate a stronger saline solution does not mean airway-clearance treatment has failed.
A lower concentration may still provide useful benefit.
For example, someone might find that 7% saline causes considerable wheezing and coughing, whereas 3% saline loosens their sputum sufficiently for them to complete their airway-clearance routine comfortably.
Another person may do perfectly well with 0.9%.
In practice there is a balance between effectiveness, tolerability and treatment burden. This individualised approach is reflected in current bronchiectasis guidance.
A treatment that is theoretically more powerful but is so unpleasant that it is rarely used may be much less useful than a gentler treatment that can be incorporated reliably into everyday life.
Where does saline fit into airway clearance?
Nebulised saline is usually an adjunct to airway clearance, rather than a replacement for it.
Airway-clearance techniques can include:
- Active Cycle of Breathing Techniques (ACBT)
- huff coughing
- positive expiratory pressure (PEP)
- oscillating PEP devices
- positioning
- exercise.
The British Thoracic Society recommends that people with bronchiectasis are taught airway-clearance techniques by a respiratory physiotherapist.
Where several inhaled treatments are prescribed, the order can also matter. BTS physiotherapy guidance gives the general sequence:
bronchodilator → mucoactive treatment such as saline → airway clearance → nebulised antibiotic and/or inhaled steroid, where prescribed.
Individual treatment plans can differ, however, so people should follow the regimen recommended by their respiratory team or physiotherapist.
What does this have to do with aspergillosis?
Many people with aspergillosis also have structural or inflammatory airway disease.
For example, bronchiectasis commonly occurs alongside allergic bronchopulmonary aspergillosis (ABPA) and may also be present in people with chronic pulmonary aspergillosis (CPA) or other chronic lung conditions.
These people can produce substantial amounts of thick sputum and sometimes mucus plugs.
Nebulised saline may therefore form an important part of managing their airway secretions and bronchiectasis.
However, saline does not kill Aspergillus and is not an antifungal treatment.
It should be thought of as part of managing mucus and airway clearance rather than as treatment for the fungal infection or allergic response itself.
The important question isn't always “Which strength is best?”
A better question may be:
“Which strength helps me clear my lungs effectively and is comfortable enough for me to keep using?”
For one person that may be 7%. For another it may be 6%, 3% or even 0.9%.
If nebulised saline causes significant wheezing, chest tightness or breathlessness, or if you are struggling to clear your sputum despite using it, discuss this with your respiratory physiotherapist or clinical team. They can review both the saline concentration and the rest of your airway-clearance technique.
Sometimes stepping down the concentration isn't stepping down the quality of treatment at all — it is finding the treatment that works best for you.
Further reading
- British Thoracic Society guideline for bronchiectasis in adults
- British Thoracic Society bronchiectasis resources
- European Respiratory Society bronchiectasis guideline